‘More Money’ Could Move To OTC Monograph Process
This article was originally published in The Tan Sheet
Executive Summary
CDER Director Woodcock is “trying to figure out ways … to get more money into” FDA’s OTC monograph work.
You may also be interested in...
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: